MONDAY, June 20, 2022 (HealthDay News) -- Area-level income and education are associated with the diagnosis of non-small cell lung cancer (NSCLC) at an advanced stage, according to a study published online June 20 in Cancer.
Anjali Gupta, from Duke University in Durham, North Carolina, and colleagues used data from the 2004 to 2016 National Cancer Database for patients aged 18 to 89 years who had been diagnosed with Stage 0 to IV NSCLC to examine the association of socioeconomic status and advanced stage at diagnosis of NSCLC by race/ethnicity and health care access measures. Data were included for 1,329,972 patients.
The researchers found that 17 and 50 percent of the non-Hispanic White and non-Hispanic Black patients, respectively, were in the lowest income quartile. The odds of an advanced-stage diagnosis were increased in association with lower area-level education and income (adjusted odds ratios, 1.12 and 1.13, respectively). These associations persisted among non-Hispanic White, non-Hispanic Black, Hispanic, and Asian patients; among those with government and private insurance; and among those treated at each facility type (community, comprehensive community, academic/research, and integrated network).
"These findings highlight the need for efforts to evaluate and address social determinants of health (specifically financial and health care access factors) as part of a comprehensive public health strategy to improve lung cancer outcomes across racial groups," the authors write.
One author disclosed financial ties to Flatiron Health.
- More African-Americans Screened for Lung Cancer With USPSTF 2021 Criteria - Consumer Health News | HealthDay ›
- Pathogenic Germline Variants ID'd in Patients With Lung Cancer - Consumer Health News | HealthDay ›
- AI Model Can Help Segment NSCLC Tumors on CT Images - Consumer Health News | HealthDay ›
- 1999 to 2018 Saw Increase in Barriers to Timely Medical Care - Consumer Health News | HealthDay ›
- Decrease Noted in Lung Cancer Cases Over Past Five Years - Consumer Health News | HealthDay ›
- More Frequent Scans Not Linked to Improved Survival After Lung Cancer Surgery - Consumer Health News | HealthDay ›
- RSNA: 20-Year Survival Shows Lung Cancer Screening Effective - Consumer Health News | HealthDay ›
- NSCLC Survival Improved With FDG PET/CT Imaging Before Radiation Therapy - Consumer Health News | HealthDay ›
- Sublobar Resection Not Inferior to Lobar Resection for T1aN0 NSCLC - Consumer Health News | HealthDay ›
- Positive Five-Year Outcomes Seen for Nivolumab in Resectable Lung Cancer - Consumer Health News | HealthDay ›
- AACR: Neoadjuvant, Adjuvant Durvalumab Beneficial for NSCLC - Consumer Health News | HealthDay ›
- Patient-Centered Approach Recommended for Oligometastatic NSCLC - Consumer Health News | HealthDay ›
- Quitting Smoking Early Linked to Lower Mortality After NSCLC Diagnosis - Consumer Health News | HealthDay ›
- Fewer Black Veterans Complete Referrals for Lung Cancer Screening - Consumer Health News | HealthDay ›
- Blood-Based Marker Plus PLCO Risk Model Can ID Lethal Lung Cancer - Consumer Health News | HealthDay ›
- Historical Redlining Adversely Impacts Cancer Screening - Consumer Health News | HealthDay ›
- Plasma ctDNA Genotyping Can Accelerate Time to Treatment for NSCLC - Consumer Health News | HealthDay ›
- Removing Race Correction From Lung Function Test Changes Clinical Management - Consumer Health News | HealthDay ›
- Reproductive Factors Linked to Risk for Lung Cancer - Consumer Health News | HealthDay ›
- Combo Immunotherapy With Durvalumab Effective for NSCLC - Consumer Health News | HealthDay ›
- Social Disadvantage Tied to Worse Lung Cancer Outcomes - Consumer Health News | HealthDay ›